Pyrimidine compounds
AssigneeSynta Pharmaceuticals Corp.
InventorsLijun Sun, Mitsunori Ono, Teresa Przewloka, Elena Kostik, Yumiko Wada
Life of this patent
Estimating the term…
Abstract
This invention features pyrimidine compounds of formula (I): each of R2 and R4 is H; R3 is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl; R5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; X is NRc; Y is covalent bond, CH2, C(O), C═N—Rc, C═N—ORc, C═N—SRc, O, S, S(O), S(O2), or NRc; Z is N or CH; one of U and V is N, and the other is CRc; and W is O, S, S(O), S(O2), NRc, or NC(O)Rc; in which each of Ra and Rb, independently, is H, alkyl, aryl, heteroaryl; and Rc is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl.
Claims32
A method for treating an interleukin-12 overproduction-related disorder, wherein the disorder is rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus, comprising administering to a subject in need thereof the compound of formula (I):
- wherein
- each of R2 and R4 is H;
- R3 is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl;
- R5 is H or alkyl;
- N is 0, 1, 2, 3, 4, 5, or 6;
- X is NRc;
- Y is covalent bond, CH2, C(O), C═N—Rc, C═N—ORc, C═N—SRc, O, S, S(O), S(O2), or NRc;
- Z is N or CH;
- one of U and V is N, and the other is CRc;
- and
- W is O, S, S(O), S(O2), NRc, or NC(O)Rc;
- in which each of Ra and Rb, independently, is H, alkyl, aryl, or heteroaryl;
- and Rc is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl;
- or a pharmaceutcally acceptable salt thereof.
A pharmaceutical composition comprising a compound of formula (I):
- wherein
- each of and R2 is R4is H;
- R3 is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl;
- R5 is H or alkyl;
- n is 0, 1, 2, 3, 4, 5, or 6;
- X is NRc;
- Y is covalent bond, CH2, C(O), C═N—ORc, C═N—SRc, O, S, S(O), S(O2), or NRc;
- Z is N or CH;
- one of U and V is N, and the other is CRc;
- and
- W is O, S, S(O), S(O2), NRc, or NC(O)Rc;
- in which each of Ra and Rb, independently, is H, alkyl, aryl, or heteroaryl;
- and Rc is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl;
- or a pharmaceutically acceptable salt thereof;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.